Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
OncoResponse
AddedFeb 15, 2024
UpdatedJun 18, 2026
OncoResponse

OncoResponse

Series B

OncoResponse Inc: A US-based biomedical services provider specializing in cancer care research and development.

HQ
Seattle, WA, US
Founded
2016
Overview
Compare
Fundraising
Employees
Website

OncoResponse Inc, founded in the United States, is a biomedical services provider with a core mission to advance cancer care through innovative research and development. The company focuses on identifying and developing therapeutic antibodies derived from the immune systems of elite cancer responders. OncoResponse aims to harness these antibodies to create effective treatments for various types of cancer, targeting the tumor microenvironment to improve patient outcomes.

Notable figures affiliated with OncoResponse include esteemed members of its Leadership Team and Scientific Advisory Board, comprising experts in oncology and immunotherapy. The company has garnered significant investment from leading venture capital firms specializing in biotech. Key achievements include the development of a robust pipeline of therapeutic candidates and successful collaborations with major research institutions. OncoResponse's impact lies in its potential to transform cancer treatment by leveraging the natural immune responses of exceptional patients.

OncoResponse - Similar Companies

Immune-Onc Therapeutics logo

Immune-Onc Therapeutics

immuneonc.com

Oncofactor logo

Oncofactor

oncofactor.com

OncoPep logo

OncoPep

oncopep.com

OncoPrecision logo

OncoPrecision

oncoprecision.bio

Cullinan Oncology logo

Cullinan Oncology

Oncolix logo

Oncolix

INmune Bio logo

INmune Bio

inmunebio.com

Cancervax logo

Cancervax

cancervax.com

Empiri logo

Empiri

empiricancer.com

Massive Bio logo

Massive Bio

massivebio.com

Meditope Biosciences logo

Meditope Biosciences

meditope.com

OnCusp Therapeutics logo

OnCusp Therapeutics

oncusptx.com

NextCure logo

NextCure

nextcure.com

OncXerna Therapeutics logo

OncXerna Therapeutics

oncxerna.com

Umoja Biopharma logo

Umoja Biopharma

OncoResponse - Quick Facts

Who are OncoResponse's competitors?

Companies similar to OncoResponse include Immune-Onc Therapeutics, Oncofactor, OncoPep and OncoPrecision.

When was OncoResponse founded?

OncoResponse was founded in 2016.

Where is OncoResponse's headquarters located?

OncoResponse's headquarters is located in Seattle, WA, US.

When was OncoResponse's last funding round?

OncoResponse's most recent funding round was for $14M (USD) in May 2023.

How much has OncoResponse raised to-date?

As of May 18, 2023, OncoResponse has raised a total of $130.1M (USD).

How many employees does OncoResponse have?

OncoResponse has 20 employees as of Feb 5, 2024.

OncoResponse - Classification

Industry
  • Professional Service Companies
Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Software
Customer
  • Enterprise
Main Product
  • Biomedical Services
Tags
  • Biotech
  • Consulting
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 13 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified